The Efficacy of HanShiYi Decoction for COVID 19 Patients: A Randomized, Controlled, Open-label Clinical trial

The Affiliated Hospital to Changchun University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Patients should meet the diagnostic criteria for patients with COVID 19 in China's New Coronary Virus Pneumonia Diagnosis and Treatment Program (Trial Ninth Version);
•2. The clinical classification is mild and common type;
•3. The first nucleic acid positive time should not exceed 48 hours;
•4. The patient's aged >=18 years old;
•5. Sign the informed consent.

•1. Patients meet the early warning indicators of severe/critical types;
•2. Patients who have used similar proprietary Chinese medicines before enrollment;
•3. Immunodeficiency diseases, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months;
•4. Women who are planning to become pregnant, pregnant women and lactating women;
•5. Patients with allergies (referring to those allergic to more than two kinds of drugs or foods, or to the known ingredients of the drug in this trial);
•6. Mental patients, or those without self-awareness;
•7. Patients not suitable to participate in clinical trials.

发起方

The Affiliated Hospital to Changchun University of Chinese Medicine